0000899243-18-016635.txt : 20180614 0000899243-18-016635.hdr.sgml : 20180614 20180614165424 ACCESSION NUMBER: 0000899243-18-016635 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180612 FILED AS OF DATE: 20180614 DATE AS OF CHANGE: 20180614 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ferro Kevin CENTRAL INDEX KEY: 0001299331 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35405 FILM NUMBER: 18899781 MAIL ADDRESS: STREET 1: C/O KOS PHARMACEUTICALS, INC. STREET 2: 1001 BRICKELL BAY DRIVE, 25TH FLOOR CITY: MIAMI STATE: FL ZIP: 33131 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MELINTA THERAPEUTICS, INC. /NEW/ CENTRAL INDEX KEY: 0001461993 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 454440364 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 GEORGE STREET STREET 2: SUITE 301 CITY: NEW HAVEN STATE: CT ZIP: 06511 BUSINESS PHONE: 312 767 0291 MAIL ADDRESS: STREET 1: 300 GEORGE STREET STREET 2: SUITE 301 CITY: NEW HAVEN STATE: CT ZIP: 06511 FORMER COMPANY: FORMER CONFORMED NAME: CEMPRA, INC. DATE OF NAME CHANGE: 20120203 FORMER COMPANY: FORMER CONFORMED NAME: Cempra Holdings, LLC DATE OF NAME CHANGE: 20090414 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-06-12 0 0001461993 MELINTA THERAPEUTICS, INC. /NEW/ MLNT 0001299331 Ferro Kevin C/O VATERA HOLDINGS LLC 499 PARK AVENUE, 23RD FLOOR NEW YORK NY 10022 1 0 1 0 Stock Option (right to buy) 7.45 2018-06-12 4 A 0 25000 0.00 A 2028-04-20 Common Stock 25000 25000 D Stock Option (right to buy) 7.45 2018-06-12 4 A 0 9100 0.00 A 2019-04-20 2028-04-20 Common Stock 9100 9100 D The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018. One-third of the shares underlying the stock option will vest and become exercisable on April 20, 2019. The remainder will vest and become exercisable in substantially equal monthly installments during the two year period commencing on April 20, 2019. /s/ Kevin Ferro 2018-06-14